Aileron Therapeutics (NASDAQ:ALRN) issued its earnings results on Wednesday. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08, Morningstar.com reports.
Shares of ALRN traded up $0.08 during trading hours on Thursday, reaching $2.13. The stock had a trading volume of 74,600 shares, compared to its average volume of 56,683. Aileron Therapeutics has a 12 month low of $1.75 and a 12 month high of $12.96. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.10. The stock has a market cap of $29.92 million, a P/E ratio of -1.21 and a beta of 0.04.
In related news, major shareholder Bioventures Ltd Novartis sold 17,508 shares of the stock in a transaction on Friday, August 17th. The stock was sold at an average price of $2.10, for a total value of $36,766.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 51,046 shares of company stock worth $114,236. 16.10% of the stock is owned by company insiders.
ALRN has been the topic of a number of recent research reports. ValuEngine upgraded Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Zacks Investment Research cut Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th.
ILLEGAL ACTIVITY NOTICE: “Aileron Therapeutics (ALRN) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS” was published by WKRB News and is owned by of WKRB News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.wkrb13.com/2018/11/09/aileron-therapeutics-alrn-releases-quarterly-earnings-results-beats-expectations-by-0-08-eps.html.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Recommended Story: How does inflation affect different investments?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.